

Long-term moderate calorie restriction inhibits inflammation without impairing cell-mediated immunity: a randomized controlled trial in non-obese humans

Simin N. Meydani¹, Sai K. Das¹, Carl F. Pieper², Michael R. Lewis³, Sam Klein⁴, Vishwa D. Dixit⁵, Alok K. Gupta⁶, Dennis T. Villareal⁷, Manjushri Bhapkar², Megan Huang², Paul J. Fuss¹, Susan B. Roberts¹, John O. Holloszy⁴, and Luigi Fontana^{4,8,9}

¹The Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA

²Duke University Medical Center, Durham, NC 27705, USA

³University of Vermont, Burlington, VT 05405, USA

⁴Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA

⁵Comparative Medicine and Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06510, USA

⁶Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA

⁷Baylor College of Medicine and Michael E DeBakey VA Medical Center, Houston, TX 77030, USA

⁸Department of Clinical and Experimental Sciences, Brescia University School of Medicine, Brescia, Italy

⁹CEINGE Biotechnologie Avanzate, Napoli, Italy

Key words: human, familial longevity, calorie restriction, inflammation, vaccine response, cell-mediated immunity

Received: 05/11/16; **Accepted:** 06/20/16; **Published:** 07/13/16

Correspondence to: Simin N. Meydani, PhD; **E-mail:** Simin.meydani@tufts.edu

Abstract: Calorie restriction (CR) inhibits inflammation and slows aging in many animal species, but in rodents housed in pathogen-free facilities, CR impairs immunity against certain pathogens. However, little is known about the effects of long-term moderate CR on immune function in humans. In this multi-center, randomized clinical trial to determine CR's effect on inflammation and cell-mediated immunity, 218 healthy non-obese adults (20-50 y), were assigned 25% CR (n=143) or an ad-libitum (AL) diet (n=75), and outcomes tested at baseline, 12, and 24 months of CR. CR induced a 10.4% weight loss over the 2-y period. Relative to AL group, CR reduced circulating inflammatory markers, including total WBC and lymphocyte counts, ICAM-1 and leptin. Serum CRP and TNF- α concentrations were about 40% and 50% lower in CR group, respectively. CR had no effect on the delayed-type hypersensitivity skin response or antibody response to vaccines, nor did it cause difference in clinically significant infections. In conclusion, long-term moderate CR without malnutrition induces a significant and persistent inhibition of inflammation without impairing key *in vivo* indicators of cell-mediated immunity. Given the established role of these pro-inflammatory molecules in the pathogenesis of multiple chronic diseases, these CR-induced adaptations suggest a shift toward a healthy phenotype.

INTRODUCTION

Calorie restriction (CR) without malnutrition is the most powerful intervention to increase lifespan in simple model organisms and rodents [1]. CR decreases inflammation, which is believed to protect against age-associated diseases [2, 3]. Low-grade chronic inflammation is deeply implicated in the pathogenesis

of multiple age-associated chronic diseases and in the biology of aging itself [4]. Serum concentrations of C-reactive protein (CRP, a highly specific systemic marker of inflammation) and TNF- α (a powerful pro-inflammatory cytokine) are both associated with an increased risk of developing insulin resistance, type 2 diabetes (T2D), cardiovascular disease (CVD) and cancer [5-8]. Excessive adiposity is associated with increased

adipose tissue TNF- α expression [9] and serum TNF- α levels [10], which are reduced by weight loss [9, 11]. However, concerns exist regarding the potential immunosuppressive effects of CR, because some studies have shown a detrimental effect on cell-mediated immune responses in monkeys [12] and increased susceptibility to infection in rodents [13, 14]. On the contrary, other studies in aging mouse and monkeys show that CR can enhance the T cell receptor diversity suggesting improved immune surveillance [15, 16].

In humans, CR including a restriction of protein and essential nutrients impairs cell-mediated immune responses [17] and increases susceptibility to morbidity and mortality from infectious diseases. However, little is known about the long-term effects of moderate CR with adequate intake of nutrients on inflammatory markers and cell-mediated immune response of healthy adults.

A purpose of this 2-year multicenter randomized controlled trial (RCT) was to evaluate the effects of a 25% CR diet on inflammatory markers [WBC count, high sensitivity CRP (hs-CRP), pro-inflammatory cytokines, adhesion molecules], and *in vivo* measures of cell-mediated immunity [antibody response to 3 vaccines,

and delayed-type hypersensitivity skin response (DTH) to three recall antigens] in a large number of healthy, non-obese young and middle-aged individuals. Self-reported infections, allergies and related medications were documented.

RESULTS

Participants and baseline characteristics

As described previously [18], 1,069 interested individuals were invited to an in-person screening evaluation, 238 started baseline testing and 220 were randomized. Two CR participants dropped prior to randomization, resulting in an ITT cohort of 218 (Figure 1 and Table 1). Thirty participants withdrew from the study [4 (5.3%) in the AL and 26 (18.2%) in the CR group ($p= 0.01$)]. Three CR participants continued the study evaluations beyond withdrawal and were included in analyses. There were no differences at baseline between AL and CR groups in biometric and demographic variables including body weight, body mass index (BMI) and other body composition and demographic variables, blood glucose or lipid profile (Table 1) or for any of the immune and inflammatory outcomes.




Figure 1. CONSORT diagram. Two hundred and thirty eight individuals were eligible and 220 individuals were randomized. Two individuals, both assigned to the calorie-restricted (CR) group, dropped out prior to starting the intervention, resulting in an intention-to-treat cohort of 218 participants; 75 in the ad libitum (AL) control and 143 in the CR group (Table 1). Thirty participants were withdrawn or dropped from the intervention prior to completion including 4 (5.3%) in the AL control group and 26 (18.2%) in the CR group ($p=0.01$).

Table 1. Demographic, anthropometric and clinical characteristics at baseline for the 218 participants who started the 2-year intervention *

	Calorie Restriction (n=143)†	Ad Libitum (n=75)†
Race		
White, n (%)	111 (77.6%)	57 (76%)
African American, n (%)	15 (10.5%)	11 (14.7%)
Other, n (%)	17 (11.9%)	7 (9.3%)
Sex (F/M)	99F/44M	53F/22M
Age, y	38.0 (7.2)	37.9 (6.9)
Height, cm	168.9 (8.6)	168.4 (8.3)
Baseline Weight, kg	71.8 (9.2)	71.3 (8.6)
Baseline BMI, kg/m ²	25.1 (1.7)	25.1 (1.6)
Body Fat, %	33.6 (6.6)	32.9 (6.1)
<i>Blood pressure</i>		
SBP, mmHg	112 (9.9)	111 (9.9)
DBP, mmHg	72.1 (7.5)	71.2 (7.1)
<i>Laboratory Values</i>		
Glucose, mg/dL	81.9 (5.6)	83.6 (6.1)
Insulin, μ IU/mL	5.4 (0.2)	5.8 (0.3)
HDL-C, mg/dL	49.1 (13.3)	49.2 (11.7)
LDL-C, mg/dL	98.0 (26.5)	105.6 (28.6)
Tg, mg/dL	103.5 (50.5)	106.8 (59.7)
Abbreviations: AL, ad libitum control group; CR, 25% calorie restriction group; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; Tg, triglycerides.		
* Values represent mean (SD).		
† No significant between group differences for all listed variables.		

Intervention adherence and body composition

Participant adherence and changes in body composition in response to CR have been published elsewhere [19]. Energy intake was reduced by 19.5 (0.8) % (480 kcal/d) during the first 6-months of CR, and by an average of 9.1 (0.7) % (234 kcal/d) for the remaining 18-months ($p < 0.0001$ vs. AL). CR induced significant reduction in body weight [8.3 (0.3) kg (11.5%) at 1-y and a net change of 7.6 (0.3) kg (10.4%) at 2-y ($p < 0.001$)], BMI and % body fat [19]. No significant change was observed in energy intake or body composition in the AL group. Measured by DEXA, CR induced a 6.1%

(0.2) kg change in Fat Mass at 1-yr and 5.3 (0.3) kg at 2-yr, but did not change in the AL group.

Moderate CR impacts white blood cell profile

Complete blood count and differentials (CBC-Diff) stayed within normal ranges in both groups. However, compared to AL, CR significantly reduced the number of WBC at month 12 ($p = 0.03$), and 24 ($p = 0.002$) (Figure 2A). There was a trend for a correlation between changes in BMI from baseline to 24 months and that of WBC number ($r = 0.14$, $p = 0.07$) when both CR and AL groups were combined.




Figure 2. Change in the number of white blood cells and lymphocytes following 2 years of calorie restriction in humans. Panel (A) baseline values of white blood cells for ad libitum (AL) and calorie-restricted (CR) groups were $5.9 \times 10^3/\mu\text{l}$ and $6.0 \times 10^3/\mu\text{l}$, respectively. Panel (B) baseline values of lymphocytes for both AL and CR groups were $1.8 \times 10^3/\mu\text{l}$. Data are mean (SE). The P value comparisons are for AL and CR groups at indicated time points.

Compared to AL, CR significantly reduced the number of lymphocytes at month 24 ($p=0.0001$) (Figure 2B). The difference in the change in lymphocytes between CR and AL group was -0.106 at 12 months ($p=0.09$) and -0.207 at month 24. ($p<0.0001$). A significant correlation between changes in BMI from baseline to month 24 and that of lymphocytes ($r=0.20$, $p=0.006$) was observed when both CR and AL groups were combined.

While a significant difference in change in monocytes was observed between the two groups, this was mainly due to an increase in the AL group. The decrease in neutrophils in the CR group at month 24 in comparison to the AL group tended to be significant ($p=0.067$) (Supplemental Table 1). No significant differences in

the eosinophils or basophils were observed (Both groups showed a small but significant increase in basophils; these numbers stayed within normal ranges (Supplemental Table 1).

Moderate CR reduces circulating inflammatory markers

CRP (natLog) decreased significantly in the CR compared to AL group at both months 12 and 24 ($p=0.001$) (Figure 3A). The correlation between change in BMI and change in the natural logarithm of CRP trended toward significance ($r=0.15$, $p=0.05$).

Plasma TNF- α decreased significantly in both AL and CR groups at month 12 (-0.34 vs. -0.30 pg/mL;

$p=0.012$, $p=0.0024$ for AL and CR, respectively); further declines in the CR group between month 12 and 24 ($p=0.018$) resulted in a significantly higher decrease in TNF- α in CR compared to AL group at month 24 ($p=0.025$) (Figure 3B). A significant correlation between changes in BMI from baseline to 24 months and that of TNF α ($r=0.15$, $p=0.04$) was observed when both CR and AL groups were combined.

Compared to AL group, there was a significant decline in serum ICAM-1 levels in the CR group from baseline to month 12 ($P<0.0001$), however, ICAM levels in the AL group decreased significantly between month 12 and 24 ($P<0.0001$) resulting in a non-significant difference between the AL and CR groups at month 24 ($P=0.14$) (Figure 3C). A significant correlation between change in BMI from baseline to 24 months and that of ICAM-1 ($r=0.17$, $p=0.02$) was observed when both CR and AL groups were combined.

The change in leptin level was significantly greater in CR compared to AL group at both month 12 and 24 ($p<0.0001$) (Figure 3D). In addition, a significant correlation was observed between changes in BMI from baseline to month 24 months and changes in leptin when both CR and AL groups were combined ($r=0.60$, $p=0.001$).

No significant changes were observed for IL-6, IL-8, and MCP-1 (data not shown).

Response to vaccine

Antibody responses to vaccines were measured at the end of the intervention. Three vaccines, Hepatitis A (HEP-A) (primary T cell-dependent), tetanus/diphtheria (TD) (secondary T cell-dependent) and pneumococcal (B cell dependent) (PN) were administered at month 17. A booster shot for HEP-A was administered at month




Figure 3. Change in plasma concentrations of inflammation markers following 2 years of calorie restriction in humans. Panel (A) baseline values of C-reactive protein (hs-CRP) for ad libitum (AL) and calorie-restricted (CR) groups were 1.1 and 1.5 $\mu\text{g/ml}$, respectively. Panel (B) baseline values of tumor necrosis factor-alpha (TNF- α) for AL and CR groups were 3.1 and 3.5 pg/ml , respectively. Panel (C) baseline values of intercellular adhesion molecule-1 (ICAM-1) for AL and CR groups were 165.4 and 165.0 ng/ml , respectively. Panel (D) baseline values of leptin for AL and CR groups were 17.7 and 16.9 ng/ml , respectively. Data are mean (SE). The P value comparisons are for AL and CR groups at indicated time points.

23. Blood for antibody response was collected at month 17 (before vaccination), 18, and 24 (after vaccination) for all vaccines, and 23 for before HEP-A booster. There was no significant difference between AL and CR groups in pre-vaccination (month 17 and 23) or post-vaccination (month 18 and 24) levels of antibodies to Hepatitis A HEP-A, TD), or any of the PN IgG serotypes (1, 2, 3, 4, 5, 6, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) (Supplemental Table 3).

For HEP-A antibody level, the majority of subjects within both AL and CR groups had levels above the

detection limit and thus quantitative values could not be obtained. However, there were no differences between AL and CR groups in % participants who had values above the detection limit at any time point for HEP-A or other vaccines.

DTH

There was no significant difference at baseline between AL and CR groups in the diameter of induration at 24 or 48 h for individual antigens or for total diameter of induration (Table 2), nor in number of positive antigens.

Table 2. Effect of calorie restriction on delayed-type hypersensitivity skin response at 48 hours*

Variable	Time point		
	Baseline	Month 12	Month 24
Trichophyton (diameter of induration, mm)			
AL	0.9 (0.3)	2.2 (0.6)	3.1 (0.8)
CR	1.5 (0.4)	1.1 (0.5)	1.8 (0.7)
p-value	0.79	0.294	0.381
Tetanus (diameter of induration, mm)			
AL	12.1 (1.1)	10.5 (1.3)	9.7 (1.1)†, ‡
CR	13.5 (1.0)	10.5 (1.0)†	8.0 (0.9)†
p-value	0.812	1	0.407
Candida (diameter of induration, mm)			
AL	7.5 (0.9)	9.2 (1.3)	9.4 (1.2)
CR	9.5 (0.8)	10.0 (1.0)	8.7 (0.9)
p-value	0.167	1	1
Total Diameter of Induration (mm) for all observed values			
AL	20.5 (1.7)	20.6 (2.2)	21.5 (1.9)
CR	24.4 (1.4)	21.2 (1.6)	18.2 (1.6)†, §
p-value	0.127	1	0.353
Number of Positive Responses (≥ 5mm)			
AL	1.48 (0.09)	1.64 (0.11)	1.72 (0.13)
CR	1.59 (0.07)	1.69 (0.08)	1.59 (0.07)
p-value	0.392	0.737	0.361
Abbreviations: AL, ad libitum control group; CR, 25% calorie restriction group. * Results are mean (SE). Predicted values based on statistical analysis. † Significantly different from baseline within each treatment group at p<0.05. ‡ p<0.016 for response to <i>Tetanus toxoid</i> . § p<0.001 for total diameter of induration.			

There were no significant main effects of treatment or time and their interaction or in the change during 2-years in the total number of positive antigens or total diameter of induration for positive responses ($\geq 5\text{mm}$) or all observed responses at 24 or 48 hours between CR and AL groups. A significant within CR group change from baseline to month 24 ($p=0.001$) in total diameter of induration (Table 2) was observed and both groups showed a significant decline in the diameter of induration for positive responses (values $\geq 5\text{mm}$) to *Tetanus toxoid* ($p=0.016$). The reason for this decline is not clear and cannot be explained by any methodological inconsistency, changes in participants' health status, timing of administration of DTH, or timing of tetanus vaccination.

Infection

Incidence of total infections or organ-specific infections, allergies and associated medications as well as severity of infections and allergies over the 24-month follow-up did not significantly differ between AL and CR groups (Supplemental Tables 3A and B). This was true for the annualized rate of infection and allergies with the exception of lower respiratory (CR group tended to have a lower rate 0.046 vs 0.015; $p=0.058$) and eye infections (CR group had a higher rate 0.00 vs 0.019; $p=0.036$) (Supplemental Table 3A).

DISCUSSION

This is the first RCT to test the long-term effects of moderate CR without malnutrition in a large sample of young and middle-aged non-obese individuals using a variety of inflammatory and immune outcomes. We show that 25% CR for 24 mo persistently reduced circulating inflammatory markers including WBC count. Serum concentrations of CRP and TNF- α were about 40% and 50% lower in the CR group, respectively. Furthermore, despite a major reduction in body fat and circulating leptin levels, a significant impairment in key *in vivo* measures of adaptive immune function with CR was not observed in our study and this finding is supported by the lack of clinically significant differences in self-reported infection rate between CR and AL groups.

Low-grade chronic inflammation is implicated in the pathogenesis of multiple age-associated chronic diseases and in the biology of aging itself [4]. On the other hand, research on rodents housed in pathogen-free facilities and data from undernourished children and adults living in third world countries suggest that a chronic reduction in energy intake may impair adaptive immunity against pathogens by lowering leptin and

other nutrient-sensing pathways [17, 20]. While data from animal and observational human studies show that CR without malnutrition inhibits inflammation [3, 20-22], this RCT is the first to show a causal relationship in humans. The WBC count has been broadly used as a non-specific marker of systemic inflammation [23], with higher levels, even when within the clinical reference range, associated with an increased risk of developing insulin resistance, T2D [24], hypertension [25], CVD [26], and cancer [27]. Moreover, the relative risk of CVD and cancer mortality increases in a dose-dependent manner with increasing WBC count, independent of other risk factors [28]. Data from previous weight loss studies in obese individuals have shown that CR reduces total WBC count, IL-1 β , IL-6, and TNF- α [29]. We found that CR induced a significant reduction in total WBC, lymphocyte and monocyte count, as well as a strong trend ($p=0.067$) for a decrease in neutrophils, suggesting that CR has metabolic benefits even in non-obese individuals. The anti-inflammatory effect of CR is further supported by the CR-induced decrease in serum levels of CRP, TNF- α , ICAM-1, and leptin [30]. However, in our study the serum concentrations of other pro-inflammatory cytokines and chemokines (IL-6, IL-8, MCP-1) were not significantly altered by CR, probably because our volunteers were healthy, young to middle-aged and non-obese, with relatively low levels of visceral adiposity [31]. Since obesity-associated increase in circulating IL-6 is mainly contributed by increased output from the visceral adipose tissue [31], it is possible that a reduction in visceral fat mass would lead to more pronounced IL-6-lowering effect in an obese individual relative to their non-obese counterpart with an already low IL-6 level.

The mechanisms underlying the anti-inflammatory effect of CR are not entirely clear. It is hypothesized that the reductions in fat mass and leptin largely explain the beneficial effect of CR on inflammation. However, our findings suggest that other metabolic and molecular factors may play a role, because peak reduction in circulating leptin levels at month 12 were not accompanied by a significant reduction in serum TNF- α levels. Thus, the significant reduction in CRP and TNF- α concentrations observed at 24 months may be due to CR-induced alterations of the neuroendocrine system through the down-regulation of nutrient-sensing pathways that impact mitochondrial function, redox status and inflammatory gene activation [32-35].

A major finding of this study is the lack of significant negative effects of CR on key *in vivo* indicators of cell-mediated immunity. There is controversy in the literature regarding the impact of CR on cell-mediated

immunity. Although some animal studies indicate that age-associated impairment of immune function may be improved by CR, and short-term CR in a small number of subjects improved T cell-mediated function [36], others have raised concern regarding the potential adverse impact of CR on cell-mediated immunity and resistance to pathogens. For example, CR mice were shown to have lower natural killer cell activity, decreased survival, and delayed viral clearance compared to ad-libitum fed mice [13, 14], which can be reversed by re-feeding [37]. CR also caused higher mortality from polymicrobial sepsis [38] and West Nile Virus [39], and more susceptibility to the intestinal parasite (*Heligmosomoides bakeri*) infection [40] in mice. In this study, despite a ~57% decrease in leptin, CR did not exert any detrimental effect on the two best available *in vivo* indicators of acquired (specific) immunity, i.e., antibody production to vaccines and DTH to recall antigens. This difference might be due to moderate level of CR (25%) administered in the current study compared to that used in several animal studies which can be as high as 40%. Taken together, these results suggest that moderate CR without malnutrition is safe and does not adversely affect immune response to pathogens, which is also supported by the lack of clinically significant differences in self-reported infection rate between CR and AL groups. It will be interesting to determine if lower than 25% CR would be effective in reducing inflammation.

In conclusion, data from this unique RCT showed that moderate long-term CR without malnutrition decreases inflammation in non-obese, healthy adults, as demonstrated by reduced number of WBC, lymphocytes, and neutrophils in blood, as well as reduced circulating levels of CRP, leptin, TNF- α , and ICAM-1, with no significant adverse effect on key *in vivo* indicators of cell-mediated immunity. These CR-induced changes suggest a shift toward a healthy phenotype, given the established role of these pro-inflammatory molecules as risk markers in the development of metabolic syndrome and age-related chronic diseases, in particular CVD, T2D and cancer.

METHODS

Overview. The Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) Phase 2 Study was a two-year, multi-center, parallel-group, single-blind RCT of healthy individuals receiving an intervention to reduce energy intake by 25% (CR) or maintain habitual ad libitum intake (AL-control) group. Clinical outcomes were assessed every 6-mo as detailed elsewhere [19, 41]. The study protocol (ClinicalTrials.gov ID:NCT00427193), was approved

by the institutional review boards at all research sites, and participants provided written informed consent. Exclusion criteria for administration of vaccine and/or DTH included history of allergic reactions, infection or exposure to antibiotics in the previous two-weeks, non-steroidal anti-inflammatory drugs within 72 h, vaccination within last 6-wk, steroids >10 mg/d, or any immunosuppressive medication. For Hepatitis A only participants were screened out of the vaccination testing if they had previously received a vaccination.

Baseline testing was conducted over six weeks and included evaluations of health status and doubly labeled water (DLW) measurements of energy expenditure to individualize the 25% CR prescription. Fasting blood samples were collected for immune parameters. DTH and vaccines were administered as indicated below.

Following baseline testing, participants were randomized to either AL or CR in a 2:1 allocation in favor of CR. Randomization was stratified by site (3 sites), sex, and BMI (normal weight, overweight).

The intervention targeted an immediate and sustained 25% CR [42, 43]. Control participants were advised to continue their current diets. No specific level of physical activity was recommended. Percent CR was calculated and adherence evaluated from DLW measurements at months 12 and 24 [43]. Participants (both CR and AL) received a multivitamin and mineral supplement (Nature Made Multi Complete, Pharmavite, Mission Hills, CA) plus a calcium supplement (1000 mg/d, Douglas Laboratories, Pittsburgh, PA) to ensure current recommendations for micronutrients were met regardless of the intervention allocation.

Outcome assessments. Participants were weighed in a pre-weighed hospital gown after an overnight fast (Scale Tronix 5200, White Plains, NY). Height was measured twice using a wall-mounted stadiometer. Percent body fat, lean mass, and bone were measured by dual X-ray absorptiometry (DXA; Hologic Inc., Bedford, MA) and analyzed using Hologic software version Apex 3.3.

As part of safety testing, participants record signs, symptoms, adverse events, and medication use in a diary and hematology, serum chemistry and urinalysis were monitored every 3-mo [41]. Self-reported infection, allergy, and antibiotic use and duration were recorded throughout the study and coded for severity (mild, moderate, and severe) by the Coordinating Center in accordance with MedRA version 14.1 and WHO Drug Dictionary Enhanced-March 2012 guidelines.

Immune and inflammatory markers. Inflammatory markers were measured in fasting blood at baseline, month 12 and 24, and analyzed at the University of Vermont. Hs-CRP was measured using particle-enhanced immunonephelometric assay (BN II, Siemens, Deerfield, IL; CV=3.2 ± 2.5%); TNF- α , monocyte chemoattractant protein-1 (MCP-1), leptin, IL-1 β , and IL-8 using the multiplex immunoassay (Human Adipokine Panel B, Millipore, Billerica, MA; Bio-Plex 200, Bio-Rad Laboratories, Hercules, CA; CV=6.1±1.7%, 6.4±2.1%, 4.3±1.5%, 8.0±4.4% and 8.7±3.9%, respectively); and IL-6 and intracellular adhesion molecule-1 (ICAM-1) using ELISA (R&D Systems, Minneapolis, MN; CV=7.9±3.1% and 8.2±1.2%, respectively). Complete blood count and WBC differential (CBC-Diff) were assayed using automated methods (Esoterix Inc., a LabCorp Company, Cranford, NJ).

In vivo cell-mediated immunity was assessed using delayed type hypersensitivity skin response (DTH) and antibody response to 3 vaccines. DTH, which determines ability of immune response to antigens to which it has been previously exposed, was assessed using Mantoux test. Three recall antigens [*Tetanus toxoid* (Aventis Pasteur), *Candida albicans* (Candin; Allermid Laboratories, San Diego, CA), and *Trichophyton* species (*Trichophyton mentagrophytes* in conjunction with *Trichophyton rubrum*; Hollister-Stier Labs, Spokane, WA)] and a negative control (0.9% normal saline) were used. Antigens were employed in a standard volume of 0.1 mL except *Tetanus toxoid* [0.025 mL (0.2 limit of flocculation units per dose)] and were injected intradermally on the volar surface of the forearm by trained research staff. Vertical and horizontal diameters of induration after 24 and 48 h were measured, and mean values ≥ 5 mm were considered positive. Total diameter of induration was calculated from sum of the means of the 3 antigens.

Antibody responses to vaccines were measured at the end of the intervention. Three vaccines, Hepatitis A (HEP-A) (primary T cell-dependent), tetanus/diphtheria (TD) (secondary T cell-dependent) and pneumococcal (B cell dependent) (PN) were administered at month 17. A booster shot for HEP-A was administered at month 23. Blood for antibody response was collected at month 17 (before vaccination), 18, and 24 (after vaccination) for all vaccines, and 23 for before HEP-A booster. Anti-HEP-A virus (anti-HAV) antibodies (total immunoglobulin, IgM and IgG) were measured by chemiluminescent immunoassay (Elecsys, Roche Diagnostics, Indianapolis, IN; CV=1.9 ± 1.4%), anti-diphtheria, and anti-tetanus toxoid IgG antibodies by EIA, and anti-*Streptococcus pneumoniae* IgG antibodies (23 serotypes)

by microsphere photometry at Mayo Medical Laboratories, Rochester, MN.

Complete blood count with differentials(CBC). CBC and white cell differential were assayed using automated methods employed by Esoterix Inc. (A LabCorp Company, Cranford, NJ)

Infection, asthma, allergies and antibiotic use. Self-reported infection, and asthma, allergy and antibiotic use, and their start and end date were recorded throughout the intervention period and coded based on severity (mild, moderate and severe) by the Coordinating Center in accordance with MedRA version 14.1 and WHO Drug Dictionary Enhanced-March 2012 guidelines.

Statistical methods. Methods for the overall CALERIE study have been described elsewhere [19]. Briefly, intention-to-treat analysis was performed by including all available observations. For continuous outcomes (CBC-Diff and inflammatory markers) repeated Mixed models analysis [44-46] were used to examine change from baseline, controlling for site, sex, BMI stratum, and the baseline value for the outcome of interest. Significant between-group differences at each time point were tested at $\alpha=0.05$. Bonferroni correction was applied where appropriate [47] for between group p values while within group changes p-values were always protected by a Bonferroni correction.

For values beyond the limits of detection of the assay for antibody response, a parametric regression model used in survival analysis [48] was applied. Values above or below detection limits were considered censored at those points. Between-group tests were performed using the lognormal distribution for the outcome adjusting for site, sex, and BMI stratum.

For the three DTH antigens, individual positive values were analyzed using the generalized estimating equation model [49] with the logit link and the Bernoulli variance. The number of positive antigens (0, 1, 2 or 3) was treated as a binomial outcome and analyzed in a similar manner. The induration diameters were treated as continuous and were analyzed using the repeated measures model described above.

The annualized infection, allergy, and associated medication rates were derived as the total number of episodes (or drugs) divided by the amount of follow-up time. For any outcome, a between-group comparison was performed using a generalized linear model [50] with the *ln* link and the Poisson variance, adjusting for site, sex and BMI stratum; the natural logarithm of the

amount of follow-up time contributed by each participant was included as an offset. The incidence of any infection was treated as a binary outcome, and analyzed using the same *In*-Poisson model with the modification suggested by Zou [51].

All analyses were performed by the statistical unit at Duke University Clinical Research Institute (DCRI, Durham, NC) using SAS software version 9.2 (SAS Institute Inc., Cary, NC).

Funding

The National Institute on Aging, National Institutes of Health Cooperative Agreements (U01AG022132, U01AG020478, U01AG020487, and U01AG020480); USDA Specific Cooperative Agreement #58-1950-0-014.

Clinical Trial Registry Number and Website

CALERIE, ID:NCT00427193, ClinicalTrials.gov.

Conflict of Interests Statement

None of the authors have conflict of interest.

REFERENCES

1. Fontana L, Partridge L and Longo VD. Extending healthy life span--from yeast to humans. *Science*. 2010; 328:321-26.
2. Franceschi C and Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci*. 2014; 69 Suppl 1:4-9.
3. Meyer TE, Kovacs SJ, Ehsani AA, Klein S, Holloszy JO and Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. *J Am Coll Cardiol*. 2006; 47:398-402.
4. Howcroft TK, Campisi J, Louis GB, Smith MT, Wise B, Wyss-Coray T, Augustine AD, McElhaney JE, Kohanski R and Sierra F. The role of inflammation in age-related disease. *Aging (Albany NY)*. 2013; 5:84-93. doi: 10.18632/aging.100531.
5. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. *Int J Cardiol*. 2013; 168:5126-34.
6. Hotamisligil GS, Shargill NS and Spiegelman BM. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science*. 1993; 259:87-91.
7. Lavie CJ, Milani RV, Verma A and O'Keefe JH. C-reactive protein and cardiovascular diseases--is it ready for primetime? *Am J Med Sci*. 2009; 338:486-92.
8. Taube A, Schlich R, Sell H, Eckardt K and Eckel J. Inflammation and metabolic dysfunction: links to cardiovascular diseases. *Am J Physiol Heart Circ Physiol*. 2012; 302:2148-65.
9. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R and Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. *J Clin Invest*. 1995; 95:2111-19.
10. Zahorska-Markiewicz B, Janowska J, Olszanecka-Glinianowicz M and Zurakowski A. Serum concentrations of TNF- α and soluble TNF- α receptors in obesity. *Int J Obes Relat Metab Disord*. 2000; 24:1392-95.
11. Formoso G, Taraborrelli M, Guagnano MT, D'Adamo M, Di Pietro N, Tartaro A and Consoli A. Magnetic resonance imaging determined visceral fat reduction associates with enhanced IL-10 plasma levels in calorie restricted obese subjects. *PLoS One*. 2012; 7:52774.
12. Roecker EB, Kemnitz JW, Ershler WB and Weindruch R. Reduced immune responses in rhesus monkeys subjected to dietary restriction. *J Gerontol A Biol Sci Med Sci*. 1996; 51:276-79.
13. Gardner EM. Caloric restriction decreases survival of aged mice in response to primary influenza infection. *J Gerontol A Biol Sci Med Sci*. 2005; 60:688-94.
14. Ritz BW, Aktan I, Nogusa S and Gardner EM. Energy restriction impairs natural killer cell function and increases the severity of influenza infection in young adult male C57BL/6 mice. *J Nutr*. 2008; 138:2269-75.
15. Messaoudi I, Warner J, Fischer M, Park B, Hill B, Mattison J, Lane MA, Roth GS, Ingram DK, Pickler LJ, Douek DC, Mori M and Nikolich-Zugich J. Delay of T cell senescence by caloric restriction in aged long-lived nonhuman primates. *Proc Natl Acad Sci U S A*. 2006; 103:19448-53.
16. Yang H, Youm YH and Dixit VD. Inhibition of thymic adipogenesis by caloric restriction is coupled with reduction in age-related thymic involution. *J Immunol*. 2009; 183:3040-52.
17. Schaible UE and Kaufmann SH. Malnutrition and infection: complex mechanisms and global impacts. *PLoS Med*. 2007; 4:115.
18. Stewart TM, Bhapkar M, Das S, Galan K, Martin CK, McAdams L, Pieper C, Redman L, Roberts S, Stein RI, Rochon J and Williamson DA. Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy Phase 2 (CALERIE Phase 2) screening and recruitment: methods and results. *Contemp Clin Trials*. 2013; 34:10-20.
19. Ravussin E, Redman LM, Rochon J, Das SK, Fontana L, Kraus WE, Romashkan S, Williamson DA, Meydani SN, Villareal DT, Smith SR, Stein RI, Scott TM, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. *J Gerontol A Biol Sci Med Sci*. 2015; 70:1097-1104.
20. Lam QL and Lu L. Role of leptin in immunity. *Cell Mol Immunol*. 2007; 4:1-13.
21. Ershler WB, Sun WH, Binkley N, Gravenstein S, Volk MJ, Kamoske G, Klopp RG, Roecker EB, Daynes RA and Weindruch R. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. *Lymphokine Cytokine Res*. 1993; 12:225-30.
22. Fontana L. Neuroendocrine factors in the regulation of inflammation: excessive adiposity and calorie restriction. *Exp Gerontol*. 2009; 44:41-45.
23. Rienstra M, Sun JX, Magnani JW, Sinner MF, Lubitz SA, Sullivan LM, Ellinor PT and Benjamin EJ. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). *Am J Cardiol*. 2012; 109:533-37.
24. Lorenzo C, Hanley AJ and Haffner SM. Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study. *Diabetologia*. 2014; 57:83-92.

25. Shankar A, Klein BE and Klein R. Relationship between white blood cell count and incident hypertension. *Am J Hypertens.* 2004; 17:233-39.
26. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH, Jr., Howard BV, Assaf AR and Prentice R. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. *Arch Intern Med.* 2005; 165:500-508.
27. Toriola AT, Cheng TY, Neuhaus ML, Wener MH, Zheng Y, Brown E, Miller JW, Song X, Beresford SA, Gunter MJ, Caudill MA and Ulrich CM. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. *Int J Cancer.* 2013; 132:2648-58.
28. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R and Mitchell P. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. *Arch Intern Med.* 2006; 166:188-94.
29. Chae JS, Paik JK, Kang R, Kim M, Choi Y, Lee SH and Lee JH. Mild weight loss reduces inflammatory cytokines, leukocyte count, and oxidative stress in overweight and moderately obese participants treated for 3 years with dietary modification. *Nutr Res.* 2013; 33:195-203.
30. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD and Diehl AM. Leptin regulates proinflammatory immune responses. *FASEB J.* 1998; 12:57-65.
31. Fontana L, Eagon JC, Trujillo ME, Scherer PE and Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. *Diabetes.* 2007; 56:1010-13.
32. Bordone L and Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. *Nat Rev Mol Cell Biol.* 2005; 6:298-305.
33. Guarente L. Mitochondria--a nexus for aging, calorie restriction, and sirtuins? *Cell.* 2008; 132:171-76.
34. Barzilai N, Huffman DM, Muzumdar RH and Bartke A. The critical role of metabolic pathways in aging. *Diabetes.* 2012; 61:1315-22.
35. Hotamisligil GS and Erbay E. Nutrient sensing and inflammation in metabolic diseases. *Nat Rev Immunol.* 2008; 8:923-34.
36. Ahmed T, Das SK, Golden JK, Saltzman E, Roberts SB and Meydani SN. Calorie restriction enhances T-cell-mediated immune response in adult overweight men and women. *J Gerontol A Biol Sci Med Sci.* 2009; 64:1107-13.
37. Clinthorne JF, Adams DJ, Fenton JI, Ritz BW and Gardner EM. Short-term re-feeding of previously energy-restricted C57BL/6 male mice restores body weight and body fat and attenuates the decline in natural killer cell function after primary influenza infection. *J Nutr.* 2010; 140:1495-1501.
38. Sun D, Muthukumar AR, Lawrence RA and Fernandes G. Effects of calorie restriction on polymicrobial peritonitis induced by cecum ligation and puncture in young C57BL/6 mice. *Clin Diagn Lab Immunol.* 2001; 8:1003-11.
39. Goldberg EL, Romero-Aleshire MJ, Renkema KR, Ventevogel MS, Chew WM, Uhrlaub JL, Smithey MJ, Limesand KH, Sempowski GD, Brooks HL and Nikolich-Zugich J. Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms. *Aging Cell.* 2015; 14:130-38.
40. Kristan DM. Chronic calorie restriction increases susceptibility of laboratory mice (*Mus musculus*) to a primary intestinal parasite infection. *Aging Cell.* 2007; 6:817-25.
41. Rochon J, Bales CW, Ravussin E, Redman LM, Holloszy JO, Racette SB, Roberts SB, Das SK, Romashkan S, Galan KM, Hadley EC and Kraus WE. Design and conduct of the CALERIE study: comprehensive assessment of the long-term effects of reducing intake of energy. *J Gerontol A Biol Sci Med Sci.* 2011; 66:97-108.
42. Pieper C, Redman L, Racette S, Roberts S, Bhapkar M, Rochon J, Martin C, Kraus W, Das S, Williamson D and Ravussin E. Development of adherence metrics for caloric restriction interventions. *Clin Trials.* 2011; 8:155-64.
43. Rickman AD, Williamson DA, Martin CK, Gilhooly CH, Stein RI, Bales CW, Roberts S and Das SK. The CALERIE Study: design and methods of an innovative 25% caloric restriction intervention. *Contemp Clin Trials.* 2011; 32:874-81.
44. Diggle PJ, Heagerty P, Liang K-Y and Zeger SL. *Analysis of Longitudinal Data.* 2002. New York: Oxford University Press.
45. Fitzmaurice G, Laird NM and Ware JH. *Applied Longitudinal Analysis.* 2002. New York City: Wiley.
46. Jennrich RI and Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. *Biometrics.* 1986; 42:805-20.
47. Wright S. Adjusted P-values for simultaneous inference. *Biometrics.* 1992; 48:1005-13.
48. Lawless J. *Statistical Models and Methods for Lifetime Data.* 2003. New York: John Wiley & Sons.
49. Liang KY. Longitudinal data analysis using generalized linear models. *Biometrika* 1986; 78:13-22.
50. McCullagh P and Nelder JA. *Generalized Linear Models.* 1989. London New York: Chapman and Hall.
51. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol.* 2004; 159:702-06.

SUPPLEMENTAL DATA

Appendix Table 1. Effect of calorie restriction on white blood cells*			
Variable (time)	Treatment Group		p-value ‡
	CR	AL	
Total monocytes (10 ³ /μL)			
Baseline	0.33 (0.01)	0.32 (0.01)	
Mo. 12	0.32 (0.01)	0.37 (0.01) †	0.004
Mo. 24	0.32 (0.01)	0.35 (0.01) †	0.034
Total Neutrophils (10 ³ /μL)			
Baseline	3.68 (0.11)	3.60 (0.13)	
Mo. 12	3.41 (0.12) †	3.71 (0.16)	0.106
Mo. 24	3.24 (0.10) †	3.54 (0.14)	0.067
Total Eosinophils (10 ³ /μL)			
Baseline	0.14 (0.01)	0.11 (0.01)	
Mo. 12	0.14 (0.01)	0.12 (0.01)	0.095
Mo. 24	0.13 (0.01)	0.15 (0.01)	0.102
Total Basophils (10 ³ /μL)			
Baseline	0.01 (0.001)	0.02 (0.002)	
Mo. 12	0.021 (0.002) †	0.025 (0.002) †	0.378
Mo. 24	0.020 (0.002) †	0.024 (0.002) †	0.443
<p>* Results are mean (SE) and reflect predicted values at months 12 and 24 based on intention-to-treat (ITT) statistical analysis, p-values reflect the ITT analyses for changes from baseline at each time point.</p> <p>† Significantly different from baseline within the same treatment group.</p> <p>‡ Values reflect difference in change from baseline between treatment groups at each time point.</p>			

Appendix Table 2. Effect of calorie restriction on antibody response to Hepatitis A, Tetanus/Diphtheria and Pneumococcal vaccines						
Time (Mos.)	Median (IQR)*			% with detectable values		
	17	18	24	17	18	24
Hepatitis A (IU/L)						
AL	9.7 (7.8, 11.7)	41.7 (29.5, 53.7)	NA	42.9%	27.5%	0%†
CR	8.6 (7.5, 10.3)	37.3 (26.0, 53.0)	28.5 (16.4, 40.7)	28.0%	23.2%	5.1%†
p-value	0.601‡	0.983‡	NA	0.670	0.832	0.332
Tetanus (IU/mL)						
AL	2.43 (1.8, 3.5)	4.95 (3.8, 5.9)	3.31 (2.6, 4.1)	90.2%	51.7%	79.3%
CR	2.56 (1.7, 3.9)	4.37 (3.3, 5.7)	3.70 (2.6, 5.0)	93.1%	52.9%	79.4%
p-value	0.675	0.775	0.940	0.499‡	0.876‡	0.992‡
Diphtheria (IU/mL)						
AL	0.36 (0.2, 0.7)	1.1 (0.7, 1.9)	0.77 (0.4, 1.1)	100%	93.3%	98.3%
CR	0.35 (0.2, 0.7)	1.1 (0.7, 1.5)	0.75 (0.4, 1.3)	98%	87.3%	100%
p-value	0.350	0.644	0.901	0.273	0.416	0.196
Pneumonia IgG Serotype 1 (µg/mL)						
AL	1.5 (0.8, 4.5)	10.0 (3.7, 35.4)	8.1 (3.1, 30.5)	85.7%	95.1%	100%
CR	1.7 (0.8, 3.9)	7.0 (2.5, 23.7)	6.3 (2.9, 21.3)	77.9%	96.1%	94.6%
p-value	0.604	0.474	0.233	0.356	0.624	0.314
Pneumonia IgG Serotype 2 (µg/mL)						
AL	0.65 (0.4, 1.3)	5.5 (2.2, 9.3)	4.3 (2.1, 12.5)	88.9%	94.3%	100%
CR	0.70 (0.4, 1.5)	3.7 (1.7, 10.7)	3.5 (1.4, 9.9)	80.4%	100%	98.8%
p-value	0.437	0.553	0.296	0.185	0.448	0.456
Pneumonia IgG Serotype 3 (µg/mL)						
AL	1.0 (0.5, 2.8)	3.8 (1.6, 8.0)	2.9 (1.1, 7.7)	90.5%	98.4%	98.1%
CR	1.2 (0.5, 2.8)	3.2 (1.8, 7.1)	2.5 (1.2, 6.6)	88.3%	99.0%	98.9%
p-value	0.853	0.973	0.599	0.971	0.702	0.676
Pneumonia IgG Serotype 4 (µg/mL)						
AL	0.5 (0.2, 1.6)	1.3 (0.5, 3.6)	1.1 (0.4, 3.9)	76.2%	100%	100%
CR	0.4 (0.2, 1.0)	1.7 (0.9, 4.2)	1.2 (0.7, 3.2)	78.8%	98.1%	97.8%
p-value	0.856	0.158	0.598	0.498	1.00	1.00
Pneumonia IgG Serotype 5 (µg/mL)						
AL	2.8 (1.0, 5.2)	4.7 (2.6, 13.4)	4.1 (2.3, 11.3)	96.8%	100%	100%
CR	3.0 (1.2, 5.1)	4.5 (2.0, 12.8)	4.9 (2.1, 11.5)	95.2%	100%	100%
p-value	0.788	0.792	0.944	0.611	0.611	0.611
Pneumonia IgG Serotype 8 (µg/mL)						
AL	1.1 (0.6, 2.6)	3.5 (1.8, 7.5)	3.0 (1.5, 6.9)	100%	100%	100%
CR	1.1 (0.5, 2.6)	2.6 (1.2, 6.4)	2.6 (1.3, 5.3)	99.0%	99.0%	98.9%
p-value	0.511	0.433	0.357	0.436	0.444	0.455
Pneumonia IgG Serotype 14 (µg/mL)						
AL	3.2 (1.3, 5.2)	11.7 (4.3, 30.6)	13.6 (4.2, 29.4)	74.6%	93.4%	86.5%
CR	2.2 (1.2, 4.8)	9.7 (2.8, 31.7)	9.5 (3.0, 27.8)	72.1%	90.4%	90.3%
p-value	0.423	0.357	0.908	0.726	0.498	0.487
Pneumonia IgG Serotype 20 (µg/mL)						
AL	0.8 (0.4, 1.8)	3.0 (1.0, 11.9)	2.5 (0.9, 5.3)	79.4%	98.4%	96.2%
CR	0.8 (0.5, 1.8)	2.2 (0.9, 7.6)	2.1 (0.7, 5.9)	75.0%	94.2%	93.5%
p-value	0.777	0.215	0.514	0.723	0.503	0.910
Pneumonia IgG Serotype 6B (µg/mL)						
AL	2.5 (1.2, 5.2)	5.1 (2.8, 11.9)	4.3 (2.3, 10.2)	85.7%	93.4%	92.3%
CR	2.7 (1.4, 4.8)	5.2 (3.0, 12.7)	5.3 (2.8, 11.9)	82.7%	96.2%	92.4%
p-value	0.876	0.401	0.564	0.854	0.187	0.630

Pneumonia IgG Serotype 7F (µg/mL)						
AL	3.0 (1.7, 6.8)	5.2 (2.6, 11.4)	4.8 (2.5, 9.6)	98.4%	96.7%	98.1%
CR	2.8 (1.5, 5.3)	4.8 (2.3, 10.1)	4.8 (2.7, 9.3)	95.2%	95.2%	97.8%
p-value	0.395	0.639	0.910	0.280	0.385	0.927
Continued to next page						
	Median (IQR)*			% with detectable values		
Time (Mos.)	17	18	24	17	18	24
Pneumonia IgG Serotype 9N (µg/mL)						
AL	1.3 (0.7, 3.2)	2.4 (1.2, 8.0)	2.5 (1.2, 6.5)	90.5%	100%	100%
CR	1.4 (0.6, 3.5)	2.8 (1.2, 6.0)	2.7 (1.2, 6.3)	77.9%	95.1%	95.7%
p-value	0.140	0.633	0.674	0.083	0.734	0.457
Pneumonia IgG Serotype 9V (µg/mL)						
AL	2.1 (1.0, 4.0)	3.9 (1.3, 11.2)	4.3 (1.7, 9.1)	95.2%	96.7%	96.2%
CR	1.9 (1.0, 4.7)	3.4 (1.6, 8.2)	3.5 (1.6, 8.4)	92.3%	96.2%	96.8%
p-value	0.636	0.162	0.215	0.461	0.851	0.845
Pneumonia IgG Serotype 10A (µg/mL)						
AL	1.9 (0.9, 5.0)	3.4 (1.6, 13.9)	2.8 (1.3, 8.0)	85.7%	88.5%	92.3%
CR	2.7 (0.9, 5.0)	3.8 (1.3, 9.5)	3.0 (1.1, 8.0)	76.9%	89.4%	89.2%
p-value	0.393	0.681	0.325	0.168	0.859	0.551
Pneumonia IgG Serotype 11A (µg/mL)						
AL	1.1 (0.5, 2.2)	3.4 (1.9, 8.8)	2.9 (1.5, 6.8)	87.3%	98.4%	100%
CR	1.2 (0.5, 4.2)	4.1 (2.0, 8.6)	3.6 (1.6, 8.1)	94.2%	100%	98.9%
p-value	0.093	0.799	0.905	0.118	0.194	0.455
Pneumonia IgG Serotype 12F (µg/mL)						
AL	0.4 (0.2, 1.0)	0.6 (0.3, 2.0)	0.7 (0.3, 2.5)	81.0%	91.8%	90.4%
CR	0.6 (0.3, 2.1)	1.2 (0.4, 3.9)	1.0 (0.4, 4.1)	74.0%	92.3%	89.2%
p-value	0.626	0.211	0.395	0.308	0.908	0.830
Pneumonia IgG Serotype 15B (µg/mL)						
AL	0.8 (0.4, 1.6)	3.7 (1.7, 13.7)	3.0 (1.5, 11.9)	84.1%	98.4%	100%
CR	0.8 (0.4, 2.0)	4.1 (1.6, 13.0)	4.0 (1.6, 10.4)	84.6%	98.1%	96.8%
p-value	0.577	0.650	0.672	0.933	0.452	0.192
Pneumonia IgG Serotype 17F (µg/mL)						
AL	3.2 (1.5, 6.4)	12.1 (4.7, 21.9)	10.3 (4.0, 19.8)	85.7%	98.4%	100%
CR	3.0 (1.6, 6.0)	11.1 (5.0, 24.8)	10.8 (5.7, 19.4)	89.4%	98.1%	97.8%
p-value	0.739	0.785	0.897	0.476	0.896	0.289
Pneumonia IgG Serotype 18C (µg/mL)						
AL	0.6 (0.3, 1.4)	3.5 (1.0, 10.2)	3.4 (1.1, 9.4)	68.3%	98.4%	92.3%
CR	0.8 (0.5, 2.0)	4.4 (1.5, 10.8)	4.3 (1.3, 8.6)	71.2%	98.1%	97.8%
p-value	0.239	0.303	0.344	0.693	0.896	0.109
Pneumonia IgG Serotype 19A (µg/mL)						
AL	4.7 (2.6, 12.5)	8.5 (3.6, 24.8)	11.3 (4.8, 23.7)	76.2%	88.3%	86.3%
CR	4.3 (2.3, 9.4)	13.0 (5.7, 38.0)	12.9 (4.8, 39.2)	79.4%	89.0%	89.9%
p-value	0.798	0.451	0.581	0.628	0.611	0.957
Pneumonia IgG Serotype 19F (µg/mL)						
AL	2.7 (1.3, 5.1)	5.2 (2.6, 16.6)	3.9 (2.0, 13.8)	74.6%	86.9%	90.4%
CR	2.9 (1.5, 5.6)	8.4 (2.9, 18.0)	5.9 (2.5, 12.0)	84.6%	91.3%	93.5%
p-value	0.063	0.228	0.256	0.062	0.200	0.254
Pneumonia IgG Serotype 22F (µg/mL)						
AL	4.2 (2.1, 8.0)	5.2 (2.7, 10.2)	4.9 (2.5, 10.6)	96.8%	95.1%	98.1%
CR	3.3 (1.6, 8.8)	3.6 (2.0, 10.1)	4.5 (2.0, 9.0)	91.3%	96.2%	95.7%
p-value	0.165	0.413	0.379	0.031	0.503	0.453

Pneumonia IgG Serotype 23F (µg/mL)						
AL	7.8 (3.2, 16.4)	8.8 (3.3, 20.0)	8.1 (3.4, 21.0)	95.2%	93.4%	96.2%
CR	7.5 (2.8, 16.2)	9.3 (3.7, 21.0)	9.6 (3.5, 18.8)	92.3%	94.2%	93.5%
p-value	0.532	0.726	0.505	0.461	0.524	0.511
Pneumonia IgG Serotype 33F (µg/mL)						
AL	1.2 (0.6, 2.9)	4.3 (1.3, 13.0)	4.4 (1.5, 11.2)	85.7%	100%	98.1%
CR	0.9 (0.5, 2.4)	5.0 (1.8, 9.6)	4.2 (1.8, 12.5)	89.4%	96.2%	97.8%
p-value	0.363	0.636	0.980	0.285	0.444	0.441

* Based on observations within detectable range. IQR, Inter-Quartile Range
† For Hepatitis A values reflect those above the detectable range.
‡ p-values are from statistical analysis accounting for censoring.
NA: Since majority of values were beyond the detectable range quantitative analysis could not be performed.

Appendix Table 3A. Annualized Rate of Infections, Allergies and Associated Medications Over the 24-Month Follow-up

Event	AL (N=75)			CR (N=143)			p-value§
	Total No. Episodes*	Average No. Days†	Annualized Rate‡	Total No. Episodes*	Average No. Days†	Annualized Rate‡	
All Infections	156	14.5	1.032	239	9.8	0.897	0.2838
Total respiratory infections	115	11.9	0.761	169	7.2	0.635	0.2099
Upper respiratory infections	108	10.9	0.715	165	6.9	0.620	0.3684
Lower respiratory infections	7	1.0	0.046	4	0.2	0.015	0.0583
GI infections	7	0.2	0.046	18	0.4	0.068	0.3602
Skin infections	9	0.7	0.060	7	0.2	0.026	0.1161
Urinary track infections	6	0.5	0.040	11	0.4	0.041	0.9154
Ear infections	4	0.3	0.026	2	0.1	0.008	0.1420
Eye infections	0	0.0	0.000	5	0.1	0.019	0.0357
Oral dental infections	6	0.3	0.040	19	0.9	0.071	0.1445
Allergies	36	1.3	0.238	47	1.2	0.176	0.1912
OTC Medication Use	190	145.0	1.257	346	229.9	1.299	0.7120
Allergy Medication Use	82	55.5	0.543	138	50.8	0.518	0.7871
Antibiotics Medication Use	71	35.6	0.470	139	33.9	0.522	0.4516

* Total number of distinct episodes summed across participants in that treatment arm.
† The total number of days during which the event was prevalent across participants in that treatment arm, divided by the number of participants in that treatment group
‡ Total number of distinct events divided by the total amount of follow-up time in that treatment arm, standardized to 365 days in a calendar year.
§ The p-value is derived from the Poisson regression model comparing the number of distinct episodes between the two groups.

Appendix Table 3B. Distribution of the Severity of the Events, Pooled Across all Events Among Participants Who Experienced the Event at Least Once

Event	AL (N=75)				CR (N=143)			
	No. Pts >=1 event*	Mild†	Moderate	Severe	No. Pts >=1 event*	Mild†	Moderate	Severe
All Infections	53	70 (44.9%)	64 (41.0%)	22 (14.1%)	89	99 (41.4%)	111 (46.4%)	29 (12.1%)
Total respiratory infections	48	51 (44.3%)	51 (44.3%)	13 (11.3%)	79	71 (42.0%)	77 (45.6%)	21 (12.4%)
Upper respiratory infections	46	49 (45.4%)	47 (43.5%)	12 (11.1%)	79	70 (42.4%)	74 (44.8%)	21 (12.7%)
Lower respiratory infections	5	2 (28.6%)	4 (57.1%)	1 (14.3%)	4	1 (25.0%)	3 (75.0%)	0
GI infections	7	2 (28.6%)	1 (14.3%)	4 (57.1%)	14	6 (33.3%)	8 (44.4%)	4 (22.2%)
Skin infections	7	6 (66.7%)	3 (33.3%)	0	7	3 (42.9%)	3 (42.9%)	1 (14.3%)
Urinary track infections	4	2 (33.3%)	3 (50.0%)	1 (16.7%)	8	1 (9.1%)	10 (90.9%)	0
Ear infections	3	0	1 (25.0%)	3 (75.0%)	2	0	0	2 (100.0%)
Eye infections	0	0	0	0	4	3 (60.0%)	2 (40.0%)	0
Oral dental infections	4	3 (50.0%)	3 (50.0%)	0	7	10 (52.6%)	8 (42.1%)	1 (5.3%)
Allergies	16	27 (75.0%)	6 (16.7%)	3 (8.3%)	23	28 (59.6%)	13 (27.7%)	6 (12.8%)

* Number of participants who experienced the event at least once in that treatment arm.

† The frequency and percent of all such events pooled across all events across all participants who experienced that event at least once.